Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of 2-dose 9-valent HPV vaccine in adolescents compared with 3-dose regimen in young women
2013-001314-15Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2013
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (4 arms), sponsored by Merck & Co. Primary endpoints: Non-inferiority of GMTs in girls aged 9 to 14 years receiving 2 doses at Day 1 and Month 6 versus young women aged 16 to 26 years receiving 3 doses, Non-inferiority of GMTs in boys aged 9 to 14 years receiving 2 doses at Day 1 and Month 6 versus young women aged 16 to 26 years receiving 3 doses and 1 more. Started Nov 2013; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2013-001314-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001314-15.